November 23, 2016 - By Adrian Mccoy · 0 Comments
The stock of Abiomed Incorporated (NASDAQ:ABMD) registered an increase of 1.09% in short interest. ABMD’s total short interest was 1.76M shares in November as published by FINRA. Its up 1.09% from 1.74 million shares, reported previously. With 1.05M shares average volume, it will take short sellers 2 days to cover their ABMD’s short positions. The short interest to Abiomed Incorporated’s float is 4.44%. About 50 shares traded hands. ABIOMED, Inc. (NASDAQ:ABMD) has risen 8.72% since April 21, 2016 and is uptrending. It has outperformed by 3.39% the S&P500.
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The company has a market cap of $4.92 billion. The Firm offers care to heart failure patients. It has a 115.27 P/E ratio. The Firm operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart.
Insitutional Activity: The institutional sentiment is 0.98 in Q2 2016. Its the same as in 2016Q1. The ratio is flat, as 31 funds sold all ABIOMED, Inc. shares owned while 101 reduced positions. only 46 funds bought stakes while 83 increased positions. They now own 38.30 million shares or 7.51% less from 41.41 million shares in 2016Q1.
Navellier And Associates Incorporated holds 0.15% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 8,954 shares. Pnc Services Inc accumulated 15,125 shares or 0% of the stock. Bluemountain Mgmt Ltd Co holds 0.03% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 11,176 shares. Hanseatic Mgmt Serv, a New Mexico-based fund reported 23,141 shares. State Board Of Administration Of Florida Retirement Sys holds 0.02% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 56,473 shares. 1832 Asset Mgmt Lp, a Ontario – Canada-based fund reported 1.12M shares. Rhumbline Advisers last reported 0.03% of its portfolio in the stock. Raymond James Financial Advisors last reported 28,462 shares in the company. The Illinois-based Envestnet Asset has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Blackrock has 18,331 shares for 0% of their US portfolio. The Iowa-based Principal Gp has invested 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Ibm Retirement Fund accumulated 0.02% or 4,009 shares. Mufg Americas last reported 0% of its portfolio in the stock. Granahan Inv Inc Ma accumulated 1.28% or 321,783 shares. Congress Asset Ma holds 0.19% or 75,276 shares in its portfolio.
Insider Transactions: Since June 7, 2016, the stock had 0 insider buys, and 11 sales for $26.39 million net activity. 5,160 ABIOMED, Inc. (NASDAQ:ABMD) shares with value of $639,540 were sold by PUHY DOROTHY E. On Tuesday, June 7 the insider Greenfield Andrew J sold $937,419. On Monday, August 1 the insider THOMAS PAUL sold $1.19M. Shares for $2.13 million were sold by Howley Michael G. BOLT WILLIAM J had sold 43,366 shares worth $4.51M. $3.56 million worth of shares were sold by MINOGUE MICHAEL R on Thursday, September 22. Shares for $2.65M were sold by Weber David M.
Out of 6 analysts covering Abiomed (NASDAQ:ABMD), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Abiomed has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, August 4 by Benchmark. The company was maintained on Wednesday, August 5 by Northland Capital. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Sterne Agee CRT on Tuesday, August 18. The rating was maintained by BTIG Research on Tuesday, August 4 with “Hold”. The stock has “Outperform” rating given by Raymond James on Friday, October 30. The stock has “Outperform” rating given by Leerink Swann on Wednesday, May 4. The firm has “Buy” rating given on Tuesday, August 9 by Jefferies. The firm has “Hold” rating given on Wednesday, August 5 by Piper Jaffray.
ABIOMED, Inc., incorporated on June 4, 1987, is a well-known provider of temporary percutaneous mechanical circulatory support devices. The Firm offers care to heart failure patients. The Firm operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Firm develops, makes and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
More important recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Fool.com which released: “The Worst Mistakes Abiomed, Inc. Investors Can Make Right Now” on April 05, 2016, also Fool.com published article titled: “How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?”, Fool.com published: “Read This Before You Sell Abiomed, Inc. Stock” on March 30, 2016. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) was released by: Fool.com and their article: “Why Abiomed Inc. Shares Crashed 12% Today” with publication date: February 08, 2016.
By Adrian Mccoy